ClinicalTrials.gg
TerminatedNCT01046214Updated Nov 20, 2015

Bupropion Hydrochloride 300 mg Extended Release Tablets Under Fasting Conditions

A Phase 1 interventional study of Bupropion HCl and Bupropion HCl in Depressive Disorder, sponsored by Teva Pharmaceuticals USA. Terminated at 2 sites in United States. Open to participants aged 25 Years and older. Per ClinicalTrials.gov, last updated 2015-11-20.

Sponsored by Teva Pharmaceuticals USA (part of Teva Pharmaceutical Industries, Ltd.) · Phase 1 and Interventional

Why this study was terminated
Recruitment issues

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Randomized
Ages
25 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 318 studies in Depressive Disorder with a site in United States — 38 open to participants now, 44 under way, 2 of them phase 3. Depressive Disorder · United States.

Enrollment
256th of 274
8 · median 87
Started
2010
with 13 others
Phase 1
23 of 318
1 open now
Registered
101st of 318
by date

Among the 318 studies in Depressive Disorder with a site in United States, this one is the 256th largest by enrollment of the 274 interventional ones that give a count, is one of 14 that started in 2010, is one of 23 in phase 1, and was the 101st registered.

Depressive Disorder

855 studies on the registry are indexed under Depressive Disorder; 159 are open to participants now.

Browse Depressive Disorder studies →

Open to participants now

38 of the 318 studies in Depressive Disorder with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 116 Depressive Disorder studies recruiting now, 44 (38%) set no upper age limit and 66 (57%) stop at 75 or younger; 24 take children under 18; 25 take healthy volunteers.

This study: 25 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 318 studies in Depressive Disorder with a site in United States, or all of them as a file.
02

Study summary

The objective of this study is to evaluate the comparative bioavailability between bupropion hydrochloride 300 mg extended release tablets (Teva Pharmaceuticals USA) and Wellbutrin XL® 300 mg extended release tablets (Biovail Pharmaceuticals, Inc.) at steady-state in patients under fasting conditions.

03

Conditions studied

  • Depressive Disorder

Browse trials for

04

Who can participate

Ages eligible
25 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients, 25 years of age or older
  • Diagnosis of any depressive disorder as per DSM IV criteria (except bipolar depression and major depressive disorder with psychotic features). Note: Both patients who are or are not being treated with bupropion or other antidepressants are permitted into the study.
  • Patients must have complained of suffering from adverse events and/or lack of effect when switched from Wellbutrin XL® 300 mg to Budeprion XL™ 300 mg.
  • (kg/m2) Greater than or equal to 19 and less than or equal to 34.
  • No abnormal laboratory values
  • No clinically significant findings in a 12-lead (ECG)
  • No clinically significant findings in vital signs measurements.
  • Be informed of the nature of the study and give written consent prior to receiving any study procedure.

Exclusion criteria

Exclusion Criteria

  • Carcinoma within the last 5 years. Note: Patients with basal or squamous cell carcinoma may be permitted into the study on a case by case basis.
  • A history of epilepsy or risk for seizures.
  • A previous or current diagnosis of bipolar depression.
  • A current diagnosis of major depressive episode with psychotic features. Note: Subjects with previous diagnosis of major depressive episode with psychotic features may be included at the investigator's discretion.
  • A previous or current diagnosis of an eating disorder (e.g. bulimia, anorexia nervosa).
  • A lifetime history of schizophrenia or schizo-affective disorder.
  • Significant disease(s) or finding(s) in a physical examination determined by an investigator to pose a health concern to the patient while on study.
  • Presence of clinically significant gastrointestinal disease and/or surgery (e.g. gastric bypass surgery) or history of malabsorption within the last year.
  • Known history or presence of an allergic sensitivity to bupropion and/or any other drug substances with similar activity.
  • Expected changes in use of permitted concomitant medication that will be continued throughout the study.
  • Undergoing abrupt discontinuation of sedatives (including benzodiazepines).
  • Use of monoamine oxidase inhibitors (MAOI) within 2 weeks prior to study admission.
  • Taking medications that interact with CYP2B6 within 30 days prior to Day 1 dosing.
  • Taking levodopa, amantadine, drugs that lower seizure threshold (e.g. theophylline, systemic , antipsychotics), and/or on nicotine replacement therapy.
  • History of alcohol or drug-dependence by DSM IV criteria within 6 months prior to study admission.
  • Positive test results for:

    • surface antigen or antibody
    • Urine drugs of abuse (i.e. marijuana, amphetamines, barbiturates, cocaine, opiates, methadone, and phencyclidine) Note: any positive test result(s) for benzodiazepine(s) must be assessed by the investigator to determine whether the patient should be excluded from this study.
    • Serum hCG consistent with pregnancy (females only).
  • On a special diet within 30 days prior to study admission (e.g. liquid, protein, raw food diet).
  • Difficulty fasting or consuming standard meals.
  • Participated in another clinical trial or received an product within 45 days prior to Day 1 drug administration.
  • Donation or loss of whole blood:

    • Less than or equal to 499 mL within 30 days prior to dosing
    • Greater than or equal to 500 mL within 56 days prior to dosing Note: blood taken for routine medical evaluations totaling less than 50 mL will be permitted.
  • Females who have discontinued the use of:

    • implanted, intrauterine, or injected hormonal within 6 months prior to Day 1 drug administration, OR
    • oral, intravaginal, or patch hormonal contraceptives within 1 month prior to Day 1 drug administration
  • Females who started taking:

    • implanted or intrauterine hormonal contraceptives less than 6 months prior to Day 1 drug administration, OR
    • oral, intravaginal, patch, or injected hormonal contraceptives less than 3 months prior to Day 1 drug administration.
  • Females who are pregnant, lactating, or likely to become pregnant during the study.
  • Have had a newly applied tattoo or body piercing within 30 days prior to study admission.
  • Does not tolerate venipuncture.
  • Unable or unwilling to provide .
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Budeprion XL™

    Budeprion XL™ 300 mg Extended Release Tablet dosed once daily for 8 days, in the morning, after an overnight fast of at least 10 hours, with the reference-placebo tablet

    Drug: Bupropion HCl

  • Active comparator
    Wellbutrin XL®

    Wellbutrin XL® 300 mg Extended Release Tablet dosed once daily for 8 days, in the morning, after an overnight fast of at least 10 hours, with the test-placebo tablet

    Drug: Bupropion HCl

Interventions

  • Budeprion XL™ 300 mg Extended Release Tablet dosed once daily for 8 days, in the morning, after an overnight fast of at least 10 hours, with the reference-placebo tablet

    Also known as: Budeprion XL™

  • Wellbutrin XL® 300 mg Extended Release Tablet dosed once daily for 8 days, in the morning, after an overnight fast of at least 10 hours, with the test-placebo tablet

    Also known as: Wellbutrin XL®

06

What researchers measure

Primary outcomes

  1. Comparative bioavailability

    Time frame: 1 month

07

Study locations

2 sites
  • California Clinical Trials
    Culver City, California 90232, United States
  • California Clinical Trials
    Glendale, California 91206, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 20, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01046214
Responsible party
Sponsor
First posted
Jan 11, 2010
Start date
Jan 2010
Last update
Nov 20, 2015

Study contacts

Lev Gertsik, MD
principal investigator · California Clinical Trials

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bupropion

Start the discussion